Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride may decrease semen quality but not harm sperm production, and stopping the drug can improve semen quality; hyperprolactinemia can cause infertility but is treatable with medication.

In this study, researchers found that bulge cells in mouse hair follicles undergo transient proliferation during early anagen, indicating their role as follicular stem cells. However, another factor beyond dermal papilla proximity may be required to initiate a new anagen phase.

This study found that finasteride treatment in male rats may lead to changes in connexin 43 expression in the testes of their offspring, potentially affecting spermatogenesis.

In this study, finasteride was found to significantly reduce DHT levels and affect spermatogenic markers in rats, while DA-9401 co-treatment indicated potential ameliorative effects.

This abstract lists keywords related to various medications and therapies, but it does not provide new study results or findings.

This article reviews the commonality of androgenic alopecia in men over 30 and the use of finasteride, without reporting new research findings.

Women's ovarian hormones and adrenal androgens change throughout life, affecting hair loss and health.

This pharmacovigilance study identified 19 drugs with high potential risk for causing male infertility, including hormonal agents, antineoplastic drugs, and antidepressants, emphasizing the need for fertility counseling and possible sperm cryopreservation in reproductive-age males before using such treatments.

In this study, researchers found that high doses of rosemary extract given to lactating mother rats adversely affected their offspring, causing weight issues and damage to liver, kidney, and testis tissues, suggesting potential teratogenic risks if used during human pregnancy and lactation.

The document concludes that accurate diagnosis of male and female gonadal disorders is crucial for effective treatment and better patient outcomes.

This review discusses the traditional uses, pharmacology, clinical applications, and toxicology of Carthami flos but reports no new clinical results, aiming to inform further research on its medicinal potential.

This article reviews emerging opportunities and challenges in male reproductive medicine, including advancements and unmet needs in erectile dysfunction, androgen deficiency, and fertility, but reports no new clinical findings.

This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.

This review discusses 46,XY disorders of sex development caused by defects in androgen production and highlights the need for long-term care from experienced multidisciplinary teams, but it reports no new clinical findings.

This review discusses the molecular mechanisms of masculinization involving androgen signaling and their roles in male embryonic development and conditions like hypospadias and prostate cancer, and reports no clinical results.

This study documented the progression of exfoliative cutaneous lupus erythematosus in German shorthaired pointers and found generally poor responses to therapies, including immunomodulatory drugs and a TNF-α inhibitor.

This study reports that a young man with severe testotoxicosis maintained spontaneous fertility despite suppressed FSH levels, underscoring the importance of high intratesticular testosterone levels for spermatogenesis.

This article reviews the clinical and biochemical features of genetic mutations affecting dihydrotestosterone production and their potential role in male pseudo-hermaphroditism, but presents no new clinical results.

In this study, flutamide at therapeutic doses caused significant histological changes in the testes and epididymis of adult albino rats, reducing androgen receptor immunoreactivity and increasing estrogen receptor immunoreactivity.

This review discusses various substances that can impact male fertility and stresses that products should be confirmed 'sperm-safe' through rigorous testing, not assumptions; it reports no new study results.

This review explores the impact of various medications on male fertility, highlighting reversible negative effects from methotrexate, finasteride, and ketoconazole, while reporting no adverse fertility effects for oral retinoids and certain immunosuppressants.

This study found that discontinuing finasteride led to a significant increase in sperm counts for most men with reduced fertility, though hormone levels and other semen parameters remained unchanged.

This review discusses the risk factors and implications of sperm aneuploidy in males, and it reports no new clinical results; the authors highlight the importance of personalized assessment in assisted reproduction.

This review discusses the evaluation of hyperandrogenemia in women and hypogonadism in men across different life stages and presents biomarkers used for diagnosing male hypogonadism, reporting no new clinical results.

This review examines recent findings on COVID-19 pneumonia treatment using mesenchymal stem cells and reports no new clinical results; the authors highlight MSCs' potential due to their immunomodulatory and tissue-regenerative properties.

This study found that finasteride treatment of male rats led to changes in their male offspring's testicular gene expression, potentially affecting sperm function in response to odorant-like signals.

This review discusses various stem cell types, methods of obtaining them, their applications, and the potential use of exosomes, but reports no new clinical results.

This study found that COVID-19 infection disrupts spermatogenesis, alters testicular cell populations, and may impact male fertility by causing long-term changes in testicular function and reduced sperm quality, as observed even in patients who have recovered from the acute phase of the infection.

In this study, autologous intratesticular PRP injection was found to be a feasible and well-tolerated procedure with low complication rates and quick recovery, but the authors indicated that current evidence is insufficient to confirm its effectiveness for mTESE.

Antisense oligonucleotides show promise for treating Myotonic Dystrophy type I.